PubMed HealthSearch

Biomedical subjects

Rory J McCrimmon

Publications and source records attributed to Rory J McCrimmon.

3 recordsLinked to original sources

Factors Associated With Progression From Level 1 to Level 2 Sensor-Detected Hypoglycaemia in People With Type 1 and Insulin-Treated Type 2 Diabetes: A Post Hoc Analysis From the Hypo-METRICS Study.

AIMS: We investigated the proportion of sensor-detected hypoglycaemic (SDH) events progressing to level 2, and associated variables. MATERIALS AND METHODS: We used data from Hypo-METRICS, which recruited people with type 1 (pwT1D) and insulin-treated type 2 diabetes (pwT2D) with &#x2265;&#x2009;1 hypoglycaemic event in preceding 3&#x2009;months, wearing blinded continuous glucose monitoring devices (CGM), additional to usual monitoring modality, and FitBits for 10&#x2009;weeks. We defined: L1: SDH <&#x2009;3.9&#x2009;mmol/L for &#x2265;&#x2009;15&#x2009;min but &#x2265;&#x2009;3.0&#x2009;mmol/L; L2: SDH <&#x2009;3.9&#x2009;mmol/L with &#x2265;&#x2009;15&#x2009;min of sensor glucose <&#x2009;3.0&#x2009;mmol/L; L2 ratio&#x2009;=&#x2009;L2/(L1&#x2009;+&#x2009;L2), restricted to participants with both event types during the study period. Associations of selected variables on L2 ratio was assessed using beta regression and purposeful variable selection. RESULTS: We analysed 23&#x2009;768 SDH events from 212 pwT1D and 213 pwT2D. PwT1D were predominantly female (53% vs. 42% in T2D, p&#x2009;=&#x2009;0.023) and younger (median age 49 vs. 62&#x2009;years, p&#x2009;<&#x2009;0.001), with a higher L2 ratio (16% vs. 14%, p&#x2009;=&#x2009;0.03). Coefficient of variation (CV), OR&#x2009;=&#x2009;1.07, 95% CI&#x2009;=&#x2009;1.06-1.09 (p&#x2009;<&#x2009;0.001), and mean sensor glucose, OR&#x2009;=&#x2009;1.13, 95% CI&#x2009;=&#x2009;1.08-1.18 (p&#x2009;<&#x2009;0.001) were the principal predictors in T1D and T2D respectively; mean L1-SDH duration, weekly L1-SDH frequency, personal CGM usage, impaired awareness were not. Progression was higher during sleep than wakefulness (21% vs. 11%, p&#x2009;<&#x2009;0.001); L2 ratios during sleep did not differ by awareness status. CONCLUSIONS: Approximately one sixth of SDH events progressed to L2, with a higher proportion in T1D than T2D. The principal determinants were CV in T1D and mean glucose in T2D. Awareness status was not associated with progression risk during sleep.

Humans

Gold and Clarke Questionnaires Identify Different People With Insulin-Treated Diabetes and Impaired Awareness of Hypoglycaemia in Almost 60% of Cases: A Post Hoc Analysis From the Hypo-METRICS Study.

AIMS: Gold and Clarke questionnaires are used to identify impaired awareness of hypoglycaemia (IAH) and severe hypoglycaemic event (SHE) risk in people with diabetes (pwD). We explored their overlap, including Clarke's Hypoglycaemia Awareness Status (Clarke-HAS) subfactor, and subsection differences in SHE incidence (Gold, Clarke, overlap). MATERIALS AND METHODS: This post hoc analysis of the Hypo-METRICS study recruited pwD on insulin (type 1: T1D; type 2: T2D) with &#x2265;&#x2009;1 hypoglycaemic event in the previous 3 months. IAH was defined as Gold &#x2265;&#x2009;4, Clarke &#x2265;&#x2009;4, Clarke-HAS &#x2265;&#x2009;2. RESULTS: Gold and Clarke were completed by 232 pwT1D and 285 pwT2D (age: 47 vs. 62&#x2009;years, p&#x2009;<&#x2009;0.001; HbA1c: 56&#x2009;mmol/mol (7.3%) vs. 57&#x2009;mmol/mol (7.4%), p&#x2009;=&#x2009;0.03). IAH prevalence in T1D vs. T2D was 21% vs. 26% (p&#x2009;=&#x2009;0.1), 14% vs. 18% (p&#x2009;=&#x2009;0.2), and 41% vs. 48% (p&#x2009;=&#x2009;0.2) according to Gold, Clarke and Clarke-HAS. The overlap between Gold &#x2265;&#x2009;4, Clarke &#x2265;&#x2009;4 was 40% (T1D: 45%; T2D: 37%); between Gold &#x2265;&#x2009;4, Clarke-HAS &#x2265;&#x2009;2 it was 45% (T1D: 43%; T2D: 47%). The overlap between Gold &#x2265;&#x2009;4, Clarke &#x2265;&#x2009;4 was 41% vs. 39% in CGM vs. non-CGM users (T1D: 50% vs. 35%; T2D: 32% vs. 40%); between Gold &#x2265;&#x2009;4, Clarke-HAS &#x2265;&#x2009;2 it was 39% vs. 53% (T1D: 38% vs. 54%; T2D: 40% vs. 53%). In the IAH sample, SHE rate was lower in people found with IAH by Gold vs. Clarke, 9% vs. 53%, and in those assessed by Gold-Clarke overlap vs. Clarke, 20% vs. 53% (all p&#x2009;<&#x2009;0.001). CONCLUSIONS: Gold and Clarke show moderate consistency (37%-54%) in identifying IAH in insulin-treated diabetes, with/without CGM use, each associated with different SHE rates, indicating the two questionnaires measure different, independent aspects of IAH.

Humans